当前位置:药药网 / 数据中心 / 生物制药海外临床研究状况
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
标题(英文)
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
条件
Melanoma Stage III|Melanoma Stage IV|Unresectable Melanoma
干预
Biological: BNT111|Biological: Cemiplimab